scholarly journals Human induced pluripotent stem cell-based microphysiological tissue models of myocardium and liver for drug development

2013 ◽  
Vol 4 (Suppl 1) ◽  
pp. S14 ◽  
Author(s):  
Anurag Mathur ◽  
Peter Loskill ◽  
SoonGweon Hong ◽  
Jae Lee ◽  
Sivan G Marcus ◽  
...  
Keyword(s):  
Stem Cell ◽  
Drug Development ◽  
Pluripotent Stem Cell ◽  
Induced Pluripotent Stem Cell ◽  
Induced Pluripotent ◽  
Tissue Models

scholarly journals Human Vascular Tissue Models Formed from Human Induced Pluripotent Stem Cell Derived Endothelial Cells

2014 ◽  
Vol 11 (3) ◽  
pp. 511-525 ◽  
Author(s):  
David G. Belair ◽  
Jordan A. Whisler ◽  
Jorge Valdez ◽  
Jeremy Velazquez ◽  
James A. Molenda ◽  
...  
Keyword(s):  
Endothelial Cells ◽  
Stem Cell ◽  
Pluripotent Stem Cell ◽  
Vascular Tissue ◽  
Induced Pluripotent Stem Cell ◽  
Induced Pluripotent ◽  
Tissue Models

scholarly journals Drug Development and the Use of Induced Pluripotent Stem Cell-Derived Cardiomyocytes for Disease Modeling and Drug Toxicity Screening

2020 ◽  
Vol 21 (19) ◽  
pp. 7320
Author(s):  
Paz Ovics ◽  
Danielle Regev ◽  
Polina Baskin ◽  
Mor Davidor ◽  
Yuval Shemer ◽  
...  
Keyword(s):  
Stem Cell ◽  
Drug Development ◽  
Drug Screening ◽  
Pluripotent Stem Cell ◽  
Disease Modeling ◽  
Heart Diseases ◽  
Induced Pluripotent Stem Cell ◽  
Drug Reactions ◽  
Novel Drugs ◽  
Induced Pluripotent

Over the years, numerous groups have employed human induced pluripotent stem cell-derived cardiomyocytes (iPSC-CMs) as a superb human-compatible model for investigating the function and dysfunction of cardiomyocytes, drug screening and toxicity, disease modeling and for the development of novel drugs for heart diseases. In this review, we discuss the broad use of iPSC-CMs for drug development and disease modeling, in two related themes. In the first theme—drug development, adverse drug reactions, mechanisms of cardiotoxicity and the need for efficient drug screening protocols—we discuss the critical need to screen old and new drugs, the process of drug development, marketing and Adverse Drug reactions (ADRs), drug-induced cardiotoxicity, safety screening during drug development, drug development and patient-specific effect and different mechanisms of ADRs. In the second theme—using iPSC-CMs for disease modeling and developing novel drugs for heart diseases—we discuss the rationale for using iPSC-CMs and modeling acquired and inherited heart diseases with iPSC-CMs.

scholarly journals Human Induced Pluripotent Stem Cell as a Disease Modeling and Drug Development Platform—A Cardiac Perspective

Cells ◽  
2021 ◽  
Vol 10 (12) ◽  
pp. 3483
Author(s):  
Mohamed M. Bekhite ◽  
P. Christian Schulze
Keyword(s):  
Stem Cell ◽  
Heart Disease ◽  
Drug Development ◽  
Pluripotent Stem Cell ◽  
Human Heart ◽  
Disease Modeling ◽  
Induced Pluripotent Stem Cell ◽  
Development Platform ◽  
Induced Pluripotent

A comprehensive understanding of the pathophysiology and cellular responses to drugs in human heart disease is limited by species differences between humans and experimental animals. In addition, isolation of human cardiomyocytes (CMs) is complicated because cells obtained by biopsy do not proliferate to provide sufficient numbers of cells for preclinical studies in vitro. Interestingly, the discovery of human-induced pluripotent stem cell (hiPSC) has opened up the possibility of generating and studying heart disease in a culture dish. The combination of reprogramming and genome editing technologies to generate a broad spectrum of human heart diseases in vitro offers a great opportunity to elucidate gene function and mechanisms. However, to exploit the potential applications of hiPSC-derived-CMs for drug testing and studying adult-onset cardiac disease, a full functional characterization of maturation and metabolic traits is required. In this review, we focus on methods to reprogram somatic cells into hiPSC and the solutions for overcome immaturity of the hiPSC-derived-CMs to mimic the structure and physiological properties of the adult human CMs to accurately model disease and test drug safety. Finally, we discuss how to improve the culture, differentiation, and purification of CMs to obtain sufficient numbers of desired types of hiPSC-derived-CMs for disease modeling and drug development platform.

scholarly journals Human-relevant preclinical in vitro models for studying hepatobiliary development and liver diseases using induced pluripotent stem cells

2019 ◽  
Vol 244 (8) ◽  
pp. 702-708
Author(s):  
Pooja Chaudhari ◽  
Lipeng Tian ◽  
Zhaohui Ye ◽  
Yoon-Young Jang
Keyword(s):  
Stem Cell ◽  
Drug Development ◽  
Cell Fate ◽  
Liver Diseases ◽  
Human Liver ◽  
Pluripotent Stem Cell ◽  
Induced Pluripotent Stem Cell ◽  
Liver Development ◽  
Cell Fate Determination ◽  
Induced Pluripotent

Pharmaceutical drug development and clinical testing is associated with billions of dollars, and often the time and money spent does not result in a viable drug formulation. The pharmaceutical industry has long relied on animal models for testing efficacy, toxicity and specificity of novel drugs. However, the studies cannot be fully relied upon, as animal models are not reflective of human pathophysiology and drug response, which results in drugs being pulled from development as late as at stage IV, after billions of dollars have already been invested in such an effort. With the advent of adult-induced pluripotent stem cell technology, came an era which offered the potential of pursing human relevant developmental and pathogenesis research and drug testing on patient-induced pluripotent stem cell-derived differentiated cells, consciously reflecting human responses with regard to drug safety, toxicity, efficacy, and side effects. Specifically, human-induced pluripotent stem cell-derived hepatobiliary cells and tissues may be a more human-relevant model system to address the biggest barrier to drug safety and approval: hepatotoxicity. In this review, we address the potential of human-induced pluripotent stem cell-based hepatobiliary differentiation technology as a means to study human liver development and hepatic cell fate determination, and to model liver diseases in an effort to develop a new human-relevant preclinical platform for drug development. Impact statement In this review, we address the potential of human-induced pluripotent stem cell-based hepatobiliary differentiation technology as a means to study human liver development and cell fate determination, and to model liver diseases in an effort to develop a new human-relevant preclinical platform for drug development.

Use of 3D culture systems to generate human induced pluripotent stem cell-derived [beta]-cells in vitro

2018 ◽  
Author(s):  
Fantuzzi Federica ◽  
Toivonen Sanna ◽  
Schiavo Andrea Alex ◽  
Pachera Nathalie ◽  
Rajaei Bahareh ◽  
...  
Keyword(s):  
Stem Cell ◽  
Beta Cells ◽  
Pluripotent Stem Cell ◽  
3D Culture ◽  
Induced Pluripotent Stem Cell ◽  
Culture Systems ◽  
Induced Pluripotent
Sign in / Sign up

Export Citation Format

Share Document